HK1216853A1 - 治療胰腺癌的方法 - Google Patents

治療胰腺癌的方法 Download PDF

Info

Publication number
HK1216853A1
HK1216853A1 HK16104890.5A HK16104890A HK1216853A1 HK 1216853 A1 HK1216853 A1 HK 1216853A1 HK 16104890 A HK16104890 A HK 16104890A HK 1216853 A1 HK1216853 A1 HK 1216853A1
Authority
HK
Hong Kong
Prior art keywords
methods
pancreatic cancer
treating pancreatic
treating
taxane
Prior art date
Application number
HK16104890.5A
Other languages
English (en)
Chinese (zh)
Inventor
．德賽
N．P．德赛
．雷恩施樂
M．雷恩施乐
Original Assignee
阿布拉科斯生物科学有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51165317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1216853(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 阿布拉科斯生物科学有限公司 filed Critical 阿布拉科斯生物科学有限公司
Publication of HK1216853A1 publication Critical patent/HK1216853A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
HK16104890.5A 2013-01-11 2014-01-10 治療胰腺癌的方法 HK1216853A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361751820P 2013-01-11 2013-01-11
US61/751,820 2013-01-11
US201361752355P 2013-01-14 2013-01-14
US61/752,355 2013-01-14
US13/794,480 US9511046B2 (en) 2013-01-11 2013-03-11 Methods of treating pancreatic cancer
US13/794,480 2013-03-11
PCT/US2014/011145 WO2014110443A1 (en) 2013-01-11 2014-01-10 Methods of treating pancreatic cancer

Publications (1)

Publication Number Publication Date
HK1216853A1 true HK1216853A1 (zh) 2016-12-09

Family

ID=51165317

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104890.5A HK1216853A1 (zh) 2013-01-11 2014-01-10 治療胰腺癌的方法

Country Status (25)

Country Link
US (3) US9511046B2 (OSRAM)
EP (1) EP2943192B9 (OSRAM)
JP (3) JP6342918B2 (OSRAM)
KR (1) KR102205710B1 (OSRAM)
CN (2) CN105025893A (OSRAM)
AU (1) AU2013203699B2 (OSRAM)
BR (1) BR112015016681A8 (OSRAM)
CA (1) CA2897589C (OSRAM)
CY (1) CY1124273T1 (OSRAM)
DK (1) DK2943192T3 (OSRAM)
ES (1) ES2878145T3 (OSRAM)
HK (1) HK1216853A1 (OSRAM)
HR (1) HRP20211062T1 (OSRAM)
HU (1) HUE056612T2 (OSRAM)
IL (2) IL239739A0 (OSRAM)
LT (1) LT2943192T (OSRAM)
MX (1) MX382017B (OSRAM)
NZ (2) NZ734971A (OSRAM)
PL (1) PL2943192T3 (OSRAM)
PT (1) PT2943192T (OSRAM)
RS (1) RS62076B1 (OSRAM)
SI (1) SI2943192T1 (OSRAM)
SM (1) SMT202100377T1 (OSRAM)
WO (1) WO2014110443A1 (OSRAM)
ZA (1) ZA201504877B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2359859A1 (en) 2002-12-09 2011-08-24 Abraxis BioScience, LLC Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA2598239C (en) 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
DK2117520T3 (en) 2006-12-14 2019-01-07 Abraxis Bioscience Llc BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN
DK2155188T3 (da) * 2007-06-01 2013-11-04 Abraxis Bioscience Llc Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
AU2010236382B2 (en) 2009-04-15 2016-01-14 Abraxis Bioscience, Llc Prion-free nanoparticle compositions and methods
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
ES2600912T3 (es) 2010-03-29 2017-02-13 Abraxis Bioscience, Llc Métodos para tratar el cáncer
WO2011153010A1 (en) 2010-06-04 2011-12-08 Abraxis Biosciences, Llc Methods of treatment of pancreatic cancer
MY166014A (en) * 2010-06-07 2018-05-21 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
JP6038123B2 (ja) 2011-04-28 2016-12-07 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物の脈管内送達およびそれらの使用
SI2790675T1 (sl) 2011-12-14 2019-11-29 Abraxis Bioscience Llc Uporaba polimernih pomožnih snovi za liofilizacijo ali zamrzovanje delcev
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
CN110934852A (zh) 2013-03-14 2020-03-31 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
CA3026452C (en) 2015-06-04 2023-03-21 Crititech, Inc. Nozzle assembly and methods for use
CN116585310A (zh) 2015-06-29 2023-08-15 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
US10925852B2 (en) * 2015-06-30 2021-02-23 The Trustees Of Columbia University In The City Of New York Talc-bound compositions and uses thereof
SG11201808125RA (en) 2016-04-04 2018-10-30 Crititech Inc Methods for solid tumor treatment
WO2018169779A1 (en) * 2017-03-17 2018-09-20 ImClone, LLC Combination therapy for pancreatic cancer
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
WO2018231908A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
KR20200064112A (ko) 2017-10-03 2020-06-05 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
AU2019239953B2 (en) 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
GB201908352D0 (en) * 2019-06-11 2019-07-24 Innovation Ulster Ltd Sonodynamic therapy
EP4007640A4 (en) * 2019-08-01 2023-10-04 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
EP4051241A4 (en) 2019-10-28 2023-12-06 Abraxis BioScience, LLC PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN
WO2021156340A1 (en) * 2020-02-04 2021-08-12 Swedish Orphan Biovitrum Ab (Publ) Pdac treatment regimen
WO2024186320A1 (en) * 2023-03-09 2024-09-12 Minneamrita Therapeutics Llc Drug combination for treatment of pancreatic cancer
CN117099681B (zh) * 2023-08-28 2024-07-05 南京农业大学 一种利用紫杉醇加倍玉米单倍体的方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT693924E (pt) 1993-02-22 2004-09-30 American Biosciences Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20030068362A1 (en) 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5650156A (en) 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US6528067B1 (en) 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
PT1023050E (pt) 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
EP1171117A4 (en) 1999-04-22 2002-08-07 American Bioscience Inc LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS
AU784416B2 (en) 1999-05-21 2006-03-30 Abraxis Bioscience, Llc Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
EP2359859A1 (en) 2002-12-09 2011-08-24 Abraxis BioScience, LLC Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
KR20110079741A (ko) 2002-12-09 2011-07-07 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
CA2598239C (en) 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
AU2012201568B2 (en) 2005-02-18 2014-07-31 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
EP1874296A4 (en) 2005-04-29 2010-06-30 Kosan Biosciences Inc METHOD FOR THE TREATMENT OF SEVERAL MYELOMES USING 17-AAG OR 17-AG OR PRODRUGS OR ALL
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
AU2006284657B2 (en) 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2007297339A (ja) * 2006-04-29 2007-11-15 Torii Yakuhin Kk 癌を治療又は検査するための医薬
BRPI0622006A2 (pt) 2006-08-31 2011-12-20 Abraxis Bioscience Llc usos de proteìna-veìculo e dìmero de colchicina ou tiocolchicina, forma unitária de dosagem, composição farmacêutica e kits
DK2117520T3 (en) 2006-12-14 2019-01-07 Abraxis Bioscience Llc BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN
LT2481409T (lt) 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelės, apimančios rapamiciną ir albuminą, kaip priešvėžinį agentą
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
DK2155188T3 (da) 2007-06-01 2013-11-04 Abraxis Bioscience Llc Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
RU2010145529A (ru) 2008-04-10 2012-05-20 АБРАКСИС БАЙОСАЙЕНС ЭлЭлСи (US) Композиции гидрофобных производных таксана и их применение
MX2010011165A (es) 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
DK2276509T3 (en) * 2008-04-11 2016-09-19 Seattle Genetics Inc DETECTION AND TREATMENT OF CANCER IN PANCREAS, ovarian and other cancers
AU2009324464B2 (en) 2008-12-11 2016-05-05 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
WO2010105172A1 (en) 2009-03-13 2010-09-16 Abraxis Bioscience, Llc Combination therapy with thiocolchicine derivatives
BRPI1014160A2 (pt) 2009-04-10 2015-08-25 Abraxis Bioscience Llc Formulações de nanopartículas e aplicações das mesmas
AU2010236382B2 (en) 2009-04-15 2016-01-14 Abraxis Bioscience, Llc Prion-free nanoparticle compositions and methods
EP2435068B1 (en) * 2009-05-28 2015-03-04 Abraxis BioScience, LLC Use of 2 anti-sparc antibodies to predict response to chemotherapy
WO2011025838A1 (en) 2009-08-25 2011-03-03 Abraxis Bioscience, Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
JP2011079788A (ja) * 2009-10-08 2011-04-21 Oita Univ 膵癌に対する選択的膵動脈制癌剤注入療法と全身化学療法との併用療法、およびそれに使用する膵癌治療薬
SG10201500013SA (en) * 2010-01-05 2015-03-30 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
ES2600912T3 (es) 2010-03-29 2017-02-13 Abraxis Bioscience, Llc Métodos para tratar el cáncer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
US20130005678A1 (en) 2010-03-30 2013-01-03 Clavis Pharma Asa Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate
US20130266659A1 (en) 2010-06-02 2013-10-10 Neil P. Desai Methods of treating bladder cancer
WO2011153010A1 (en) 2010-06-04 2011-12-08 Abraxis Biosciences, Llc Methods of treatment of pancreatic cancer
MY166014A (en) 2010-06-07 2018-05-21 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
JP6038123B2 (ja) 2011-04-28 2016-12-07 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物の脈管内送達およびそれらの使用
SI2790675T1 (sl) 2011-12-14 2019-11-29 Abraxis Bioscience Llc Uporaba polimernih pomožnih snovi za liofilizacijo ali zamrzovanje delcev
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US20140199404A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CA2900668A1 (en) 2013-02-11 2014-08-14 Abraxis Bioscience, Llc Treatment of melanoma with nanoparticles comprising paclitaxel
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
AU2014228386B2 (en) 2013-03-13 2018-11-29 Abraxis Bioscience, Llc Methods of treatment of pediatric solid tumor
CN110934852A (zh) 2013-03-14 2020-03-31 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
US20170202782A1 (en) 2014-04-06 2017-07-20 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
WO2016141365A1 (en) 2015-03-05 2016-09-09 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
CN116585310A (zh) 2015-06-29 2023-08-15 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
KR20240144442A (ko) 2015-06-29 2024-10-02 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물에 대한 바이오마커
CA2990726A1 (en) 2015-06-29 2017-01-05 Abraxis Bioscience, Llc Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
US20170181988A1 (en) 2015-12-23 2017-06-29 Cipla Limited Methods for the treatment of bladder cancer

Also Published As

Publication number Publication date
ZA201504877B (en) 2016-10-26
PT2943192T (pt) 2021-07-16
BR112015016681A8 (pt) 2019-10-22
DK2943192T3 (da) 2021-07-05
NZ734971A (en) 2018-12-21
LT2943192T (lt) 2021-08-10
IL239739A0 (en) 2015-08-31
KR102205710B1 (ko) 2021-01-21
US9511046B2 (en) 2016-12-06
JP6697017B2 (ja) 2020-05-20
SMT202100377T1 (it) 2022-01-10
AU2013203699A1 (en) 2014-10-30
JP2019081790A (ja) 2019-05-30
US9855220B2 (en) 2018-01-02
RS62076B1 (sr) 2021-07-30
EP2943192A4 (en) 2016-06-01
CN109793728A (zh) 2019-05-24
SI2943192T1 (sl) 2021-09-30
US10328031B2 (en) 2019-06-25
IL272905A (en) 2020-04-30
US20180153820A1 (en) 2018-06-07
MX382017B (es) 2025-03-11
EP2943192A1 (en) 2015-11-18
NZ630230A (en) 2017-09-29
US20140199403A1 (en) 2014-07-17
BR112015016681A2 (pt) 2017-07-11
CA2897589A1 (en) 2014-07-17
HRP20211062T1 (hr) 2021-12-24
JP6342918B2 (ja) 2018-06-13
CA2897589C (en) 2021-03-02
AU2013203699B2 (en) 2016-09-08
EP2943192B1 (en) 2021-05-12
JP2016505018A (ja) 2016-02-18
CN105025893A (zh) 2015-11-04
PL2943192T3 (pl) 2022-01-24
CY1124273T1 (el) 2022-11-25
ES2878145T3 (es) 2021-11-18
KR20150103745A (ko) 2015-09-11
MX2015008898A (es) 2015-10-14
US20170020824A1 (en) 2017-01-26
JP2018087235A (ja) 2018-06-07
EP2943192B9 (en) 2021-09-29
HUE056612T2 (hu) 2022-02-28
WO2014110443A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
HK1216853A1 (zh) 治療胰腺癌的方法
HK1218506A1 (zh) 治療黑素瘤的方法
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
PH12016502066A1 (en) Methods of treating bladder cancer
NZ602382A (en) Methods of treatment of hepatocellular carcinoma
EP3134115A4 (en) Methods and compositions for treating metastatic breast cancer and other cancers in the brain
PH12016500137B1 (en) Afucosylated anti-fgfr2iiib antibodies
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
MX2015008888A (es) Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
EP3076972A4 (en) Cancer treatment with combination of plinabulin and taxane
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
EP3348276A4 (en) CANCER TREATMENT COMPOSITION COMPRISING ANTI-CD26 ANTIBODY AND ANOTHER CANCER AGENT
MX2015011752A (es) Metodos para tratar cancer de pulmon.
HK1219231A1 (zh) 治疗儿童实体瘤的方法
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
EP3242688A4 (en) Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
SG11201702129XA (en) Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers
PH12014502109A1 (en) Methods of treating cancer using aurora kinase inhibitors
EP2836217A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS